LigaChem Biosciences announced on the 21st that it will invest $25 million (about 36.5 billion won) in its UK partner, IKSUDA Therapeutics, for the purpose of management participation. Through this, LigaChem Biosciences will secure the position of largest shareholder and the pipeline rights held by ...
Samjin pharm announced on the 21st that it has newly appointed Jo Gyu-seok and Choi Ji-hyun as co-CEOs during the board meeting following the regular shareholders' meeting. Newly appointed CEO Jo Gyu-seok and CEO Choi Ji-hyun are the eldest son and daughter of co-founders Cho Ui-hwan, who was born i...
HLB's liver cancer new drug has once again sought approval from the U.S. Food and Drug Administration (FDA), but on the 21st, it faced another request for 'supplementation', resulting in disappointment. Jinjang-gon, chairman of HLB Group, held an online press briefing that morning and noted, 'The is...
The domestic pharmaceutical company HLB and China's Antengene Corporation's new drug for liver cancer did not receive approval from the U.S. Food and Drug Administration (FDA). They attempted a second FDA approval for commercialization but failed. According to HLB, the FDA sent a complete response l...
Emory Healthcare aims to predict and manage the fall risk of hospitalized patients through artificial intelligence (AI) cameras. It is also developing a service that allows AI to instantly translate doctor explanations for foreign patients. Alistair Erskine, chief information officer of Emory Health...
Samsung Bioepis and Hanmi Pharmaceutical will jointly sell the osteoporosis treatment Prolia biosimilar (a copy of a biopharmaceutical) in the domestic market. Samsung Bioepis, the developer of the drug, will be responsible for production and supply, while both companies will handle domestic marketi...
This article was published on March 18, 2025, at 2:37 p.m. on the ChosunBiz RM Report site. The Fair Trade Commission is investigating allegations that Daiso, a low-cost household goods store, interfered with the sale of health supplements by the Korea Pharmaceutical Association, which has become em...
GC Biopharma announced on the 18th that its U.S. affiliate Curevo Vaccine secured $110 million (approximately 159.4 billion won) in a Series B investment aimed at developing its shingles vaccine 'Amejosbatain' (project name CRV-101). This funding round was led by the European life sciences venture c...
Celltrion has set a target to achieve an average shareholder return rate of 40% over the next three years by 2027. The shareholder return rate refers to the ratio of money a corporation spends on dividends and share buybacks to its net income. A higher return rate is interpreted as the corporation d...
The biotechnology corporation Alteogen announced on the 17th that it signed a technology export contract with the global pharmaceutical company Astrazeneca's biopharmaceutical subsidiary MedImmune to develop an anti-cancer treatment using its human hyaluronidase source technology ALT-B4 on the 15th....
